Business Context and Reporting Period
Company: Conduit Pharmaceuticals Inc. (CDT)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2025
Business Model: Clinical-stage life science company focusing on acquiring and developing Phase 2-ready assets using AI and cybernetics, with an exit strategy via third-party licensing rather than direct commercialization.
Key Corporate Actions: Completed a 1-for-100 reverse stock split on January 24, 2025. Dr. Andrew Regan was appointed CEO effective April 15, 2025, following the resignation of Dr. David Tapolczay.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(5.15) million | $(3.55) million |
| Operating Loss | $(4.01) million | $(2.96) million |
| Cash and Cash Equivalents (End of Period) | $2.13 million | $1.84 million |
| Net Cash Used in Operating Activities | $(4.33) million | $(2.36) million |
| Net Cash Provided by Financing Activities | $5.93 million | $0 |
| Total Assets | $7.32 million | $4.19 million |
| Total Liabilities | $4.63 million | $11.0 million |
| Stockholders' Equity | $2.69 million | $(6.79) million |
Debt & Liquidity: The company repaid significant related-party convertible notes during the quarter. As of March 31, 2025, approximately $5.5 million in principal and interest remained outstanding on the A.G.P. Convertible Note. The company has approximately $12.0 million remaining available under its At-The-Market (ATM) offering program.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by $1.6 million (45%) to $5.15 million, driven primarily by a $1.8 million loss on the change in fair value of convertible notes and increased R&D expenses.
- R&D Expenses: Increased by $1.18 million (923%) to $1.31 million. This surge was primarily due to $1.1 million in expenses related to the Sarborg Service Agreement (AI/cybernetics services) and $0.1 million for the Charles River Laboratories agreement.
- Debt Reduction: Total liabilities decreased by approximately $6.4 million compared to Q1 2024. The company extinguished the August 2024 Nirland Note and repaid other related-party notes, significantly reducing current liabilities.
- Equity Position: Stockholders' equity improved from a deficit of $(6.79) million to a positive $2.69 million, largely due to the issuance of common stock via the ATM program ($8.1 million proceeds) and the conversion of debt to equity.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has concluded there is substantial doubt regarding the company's ability to continue as a going concern for at least 12 months from the filing date. The company requires additional funding to support its business plan and intends to pursue public or private equity/debt financings.
- Liquidity Plan: The company anticipates needing approximately $12.7 million for working capital over the next 12 months. It plans to fund this through the remaining ATM capacity and potential new borrowings.
- Nasdaq Compliance: The company received an extension from the Nasdaq Hearings Panel to regain compliance with listing rules (MVPHS and MVLS) and has applied to transfer to the Nasdaq Capital Market. It regained compliance with the Bid Price Rule as of February 26, 2025.
- Legal Contingencies:
- Strand Hanson: A claim for $2 million and 65,000 shares is pending; the company has accrued a $0.4 million liability.
- St George Street Capital: Disputes regarding ownership of the AZD 1656 co-crystal patent are ongoing; no loss has been accrued as the outcome is not considered probable.
- Subsequent Events: The Board authorized a $1.0 million share repurchase program in April 2025. Additionally, the A.G.P. Convertible Note holder converted an additional $1.3 million of principal/interest into shares in April 2025.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $2.13 million cash balance against the stated $12.7 million working capital requirement for the next 12 months.
- ATM Utilization: Monitor the execution of the remaining $12.0 million ATM offering to ensure liquidity needs are met without excessive dilution.
- Debt Conversion Terms: Review the terms of the A.G.P. Convertible Note ($5.5 million outstanding), specifically the conversion price floor waivers and potential dilution impact.
- Nasdaq Status: Confirm the final acceptance of the transfer to the Nasdaq Capital Market and ongoing compliance with bid price rules.
- Related Party Transactions: Scrutinize the $1.1 million Sarborg Service Agreement and the $1.5 million Sarborg Additional Agreement (paid in stock) for valuation and necessity.
- Legal Outcomes: Track the resolution of the Strand Hanson litigation and the St George Street Capital patent dispute.